Filter Results:
(226)
Show Results For
- All HBS Web
(226)
- People (2)
- News (71)
- Research (151)
- Multimedia (1)
- Faculty Publications (57)
Show Results For
- All HBS Web
(226)
- People (2)
- News (71)
- Research (151)
- Multimedia (1)
- Faculty Publications (57)
- 24 Sep 2020
- News
The Race for a Vaccine
Moderna could create a vaccine for clinical testing in just 60 days. That was three times faster than any vaccine candidate had ever been produced. Fauci didn't believe him. An idea emerged to test Bancel’s... View Details
- 01 Jun 2018
- News
Floor It
case study with the Multiple Myeloma Research Foundation, GNS Healthcare, the Moffitt Cancer Center’s ORIEN program, and biotech firm Foundation Medicine. Rethinking Drug Trials In an adaptive platform trial, different View Details
Keywords: Julia Hanna; illustration by Mengxin Li
- 01 Mar 2016
- News
Off Script
(Thinkstock) Prescription drug spending increased by more than 13 percent in the United States in 2014, raising health insurance premiums and the ire of consumers and politicians. The reasons behind the rise are many, including the high... View Details
- 13 Oct 2016
- News
Adding Muscle to the Fight Against Disease
biotech companies—as a function of cost, time, and failure modes—tend to risk pivot on one program, one clinical trial, one outcome,” he observes. “Our company is the leader in mining muscle biology for drug discoveries that translate... View Details
Keywords: Deborah Blagg
- 15 Dec 2024
- News
After Ozempic
Back before Ozempic, when Kate Mulroney (MBA 1984) spoke at technical conferences about her work at Novo Nordisk, people often assumed she was talking about Novartis. “I’d have to explain that’s a Swiss company; we’re Danish,” says Mulroney, now head of advanced... View Details
- 29 May 2001
- Research & Ideas
Genomics: Can We Start Making Money Now?
new drugs and therapies that can be tailored to individuals and result in fewer side effects. Advances in treatments of cancer and infectious diseases are likely to be early benefits of work in genomics, Lechleiter said. Another potential... View Details
Keywords: by Sean Silverthorne
- 08 Dec 2003
- Research & Ideas
Why Europe Lags in Pharmaceuticals and Biotech
the preferred testing ground for Phase 1 clinical trials of new drugs, the benefits of massive R&D spending and economic throw-offs are being enjoyed elsewhere, primarily in the United States and in an increasingly competitive Asia.... View Details
- 01 Sep 2008
- News
Mara Aspinall
a drug or device with an applicable test. Second, the FDA could increase the number of drugs that have specific label requirements for gene-based testing to identify the... View Details
- 01 Dec 2013
- News
Your Own Medicine
drug he has ever taken that directly targets his DMD, a rare degenerative disorder in boys that weakens the body's muscles, usually putting sufferers in wheelchairs in adolescence and shutting down their heart and lungs in their 20s. For... View Details
- 01 Jun 2000
- News
The Business of Biotech
biotechnology. The prospect is exhilarating, but the road to this brave new biotech world has more than a few bumps. With an average time line of ten years required to bring a drug to market - and the potential for failure looming every... View Details
Keywords: Julia Hanna
- 23 Mar 2003
- Research & Ideas
AIDS in Africa—What’s the Solution?
5th Annual Africa Business Conference at Harvard Business School on March 8. Much of the debate over AIDS in Africa has surrounded the high cost of the drugs that have turned the deadly disease into one that patients in the West can now... View Details
Keywords: by Julie Jette
- 04 Sep 2019
- News
Advancing Diagnostics that Can Save Lives
who spent six years commercializing drugs and diagnostics in East and West Africa before earning her MBA. “There are frequently delays in diagnosis, where the turnaround time for a biopsy could be several weeks or months.” That lag time,... View Details
Keywords: Susan Young
- 20 Aug 2014
- News
With No Time to Lose
an effective biomarker—a kind of test that could measure the progression of ALS over a short period of time—did not yet exist. Without it, drug trials relied on longer, more costly observations of disease... View Details
Keywords: Margie Kelley
- 01 Mar 2017
- News
Alumni Take Cold Calls in New York City
focused on 23andMe, whose sale of genetic testing kits directly to consumers was challenged by the Food & Drug Administration. Quelch, who coauthored the case, is also on the faculty of the Harvard T.H. Chan... View Details
- 14 May 2014
- News
(Re)moving the Needle
You wouldn't think that the lowly, annoying mosquito would have anything to teach researchers working on the cutting edge of drug delivery methodology, but you would be wrong. Have you ever noticed that you don't become aware of a... View Details
- 10 Oct 2017
- First Look
First Look at New Research and Ideas, October 10, 2017
in the diabetic space, became MannKind’s marketing partner and helped launch Afrezza in February, 2015. Although the drug had a black box warning and required doctors to perform a lung test on patients,... View Details
Keywords: Sean Silverthorne
- 10 Sep 2008
- Research & Ideas
Long-Tail Economics? Give Me Blockbusters!
by focusing on bigger films that require a bigger commitment." Jeff Robinov believes in blockbusters and his strategy is to create more of them. The pharmaceutical and entertainment industries are similar. R&D costs in both are high. Results are unpredictable.... View Details
- 01 Dec 2022
- News
Road to Recovery
withdrawal) and other incentives for remaining substance-free and engaging with a treatment program. The company currently offers programs for alcohol, opioids and heroin, and stimulant addiction. Participants can be prompted at random intervals to take an alcohol or... View Details
- Student-Profile
A Jay Holmgren
assisted with his father’s care. “I had this gigantic binder of test results that I would have to fax to different specialists and providers,” he explains. “I thought to myself, ‘Why do I still have this physical folder? Why don’t we have... View Details
- 06 Dec 2021
- News
Vision: Sound Science
of scientific inquiry in gene-based hearing loss and inner-ear drug delivery: “In some infants with profound hearing impairment, there’s a mutation in one of those genes that results in loss of a protein that inner-ear cells need to... View Details
Keywords: Deb Blagg